Evidence-Based Positron Emission Tomography

Abstract

progression in Deauville score 3 (40/60, 67%) was significantly different from score 2 (21/47, 45%; P = 0.023) and 4 (24/27, 89%; P = 0.030), we categorized patients into 3 groups: Deauville score 1-2, 3, and 4-5. With a median follow-up of 54.7 months (IQR, 30.2-84.5), 5-year PFS rate was 35.7% (95% CI, 30.0-41.4), and OS rate was 47.1% (95% CI, 40.8-53.4). NCCN-IPI risk and post-treatment PET-CT scan were independently associated with PFS in multivariate analysis (for LI NCCN-IPI, hazard ratio [HR] 1.615, 95% CI 0.838-3.113; HI NCCN-IPI, HR 3.063, 95% CI 1.626-5.769; high NCCN-IPI 4.475, 95% CI 2.231-8.977; P < 0.001: for post-treatment Deauville score 3, HR 1.895, 95% CI 1.281-2.801; score 4-5, HR 6.916, 95% CI 4.948-9.667; P < 0.001). We stratified patients into 5 groups based on risk of progression: low (low NCCN-IPI and Deauville score 1-2), INT-1 (low NCCN-IPI and score 3, or LI NCCN-IPI and score 1-2), INT-2 (HI NCCN-IPI and score 1-2), high (high NCCN-IPI and score 1-2, or LI to high NCCN-IPI and score 3), and very high (score 4-5). The risk model showed a strong association with PFS and OS (Figure 1). Conclusion: This study proposes a new risk stratification model incorporating baseline NCCN-IPI in combination with post-treatment Deauville score on PET-CT scan in patients with newly diagnosed nodal PTCL.